ES2385666T3 - SFRP y motivos peptídicos que interactúan con SFRP y sus métodos de uso - Google Patents

SFRP y motivos peptídicos que interactúan con SFRP y sus métodos de uso Download PDF

Info

Publication number
ES2385666T3
ES2385666T3 ES02707454T ES02707454T ES2385666T3 ES 2385666 T3 ES2385666 T3 ES 2385666T3 ES 02707454 T ES02707454 T ES 02707454T ES 02707454 T ES02707454 T ES 02707454T ES 2385666 T3 ES2385666 T3 ES 2385666T3
Authority
ES
Spain
Prior art keywords
sfrp
sequence
protein
sec
rankl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES02707454T
Other languages
English (en)
Spanish (es)
Inventor
Jeffrey S. Rubin
Aykut Uren
Nicole Joy Horwood
Matthew Todd Gillespie
Brian K. Kay
Bernard Weisblum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
St Vincents Institute of Medical Research
United States Department of Health and Human Services
Original Assignee
St Vincents Institute of Medical Research
United States Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by St Vincents Institute of Medical Research, United States Department of Health and Human Services filed Critical St Vincents Institute of Medical Research
Application granted granted Critical
Publication of ES2385666T3 publication Critical patent/ES2385666T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0643—Osteoclasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/22—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of calcitonin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
ES02707454T 2001-01-10 2002-01-10 SFRP y motivos peptídicos que interactúan con SFRP y sus métodos de uso Expired - Lifetime ES2385666T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26090801P 2001-01-10 2001-01-10
US260908P 2001-01-10
PCT/US2002/000869 WO2002055547A2 (en) 2001-01-10 2002-01-10 Sfrp and peptide motifs that interact with sfrp and methods of their use

Publications (1)

Publication Number Publication Date
ES2385666T3 true ES2385666T3 (es) 2012-07-30

Family

ID=22991151

Family Applications (1)

Application Number Title Priority Date Filing Date
ES02707454T Expired - Lifetime ES2385666T3 (es) 2001-01-10 2002-01-10 SFRP y motivos peptídicos que interactúan con SFRP y sus métodos de uso

Country Status (11)

Country Link
US (2) US7488710B2 (enExample)
EP (1) EP1387854B1 (enExample)
JP (3) JP4029041B2 (enExample)
AT (1) ATE550345T1 (enExample)
AU (1) AU2002241859B2 (enExample)
CA (1) CA2434672C (enExample)
CY (1) CY1112875T1 (enExample)
DK (1) DK1387854T3 (enExample)
ES (1) ES2385666T3 (enExample)
PT (1) PT1387854E (enExample)
WO (1) WO2002055547A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4832291B2 (ja) * 2004-03-31 2011-12-07 一男 新家 ラベル用物質とキメラ物質、これらの物質の作製方法、並びに該ラベル用物質を用いて生体物質を捕捉、構造解析又は／及び同定する方法
EP1831254B1 (en) * 2004-12-23 2012-06-06 Molmed SpA Conjugation product
WO2008061029A1 (en) * 2006-11-10 2008-05-22 Wyeth Aryl sulfonamide derivatives and methods of their use
AU2009226161A1 (en) * 2008-03-21 2009-09-24 Adlyfe, Inc. Use of pyrene to carry peptides across the blood brain barrier
PL2591683T3 (pl) * 2008-05-16 2017-07-31 Siebte Pmi Verwaltungs Gmbh Koncentraty białkowe z nasion oleistych i sposoby ich wytwarzania
JP2013006783A (ja) * 2011-06-22 2013-01-10 Nagasaki Univ 荷重感知遺伝子
PT3116521T (pt) * 2014-03-14 2024-10-15 Univ New York State Res Found Regulação neurogénica de crescimento ósseo e degradação óssea
CA2948071C (en) 2014-05-07 2022-08-30 Boehringer Ingelheim International Gmbh Container, nebulizer and use
WO2018229774A1 (en) * 2017-06-15 2018-12-20 Technion Research & Development Foundation Limited Compositions and methods for detection of genomic variations
EP3696192A1 (en) * 2019-02-15 2020-08-19 Consejo Superior De Investigaciones Científicas Therapeutic target and monoclonal antibodies against it for the diagnosis and treatment of alzheimer´s disease

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5238839A (en) * 1988-02-09 1993-08-24 Dana Farber Cancer Institute Nucleic Acids Encoding proteins which induce immunological effector cell activation and chemattraction, vectors, and recombinant cells
US5204328A (en) * 1990-06-26 1993-04-20 Merck & Co., Inc. Peptides having atrial natriuretic factor activity
JPH07503944A (ja) * 1991-11-22 1995-04-27 イエダ　リサーチ　アンド　デベロツプメント　カンパニー　リミテツド Ａｒｇ−ｇｌｙ−ａｓｐ配列の非ペプチド代替物およびそれらからなる医薬組成物
US5578569A (en) * 1993-03-12 1996-11-26 Tam; Cherk S. Method of increasing bone growth
US5536814A (en) * 1993-09-27 1996-07-16 La Jolla Cancer Research Foundation Integrin-binding peptides
US5726156A (en) 1995-03-06 1998-03-10 Trega Biosciences, Inc. Cytokine regulatory agents and methods of use in pathologies and conditions associated with altered cytokine levels
US5846932A (en) * 1993-11-12 1998-12-08 Genentech, Inc. Receptor specific atrial natriuretic peptides
US5632983A (en) 1994-11-17 1997-05-27 University Of South Florida Method for treating secondary immunodeficiency
US5861483A (en) 1996-04-03 1999-01-19 Pro-Neuron, Inc. Inhibitor of stem cell proliferation and uses thereof
AU2664797A (en) 1996-04-12 1997-11-07 Board Of Trustees Of The Leland Stanford Junior University Wnt receptor compositions and methods
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
ATE318915T1 (de) 1996-09-24 2006-03-15 Tanox Inc Genfamilie von apoptose-verwandten peptiden, dadurch kodierte peptide und verfahren zu deren herstellung
US5939271A (en) * 1997-02-19 1999-08-17 The Regents Of The University Of California Netrin receptor
EA003636B1 (ru) 1997-04-16 2003-08-28 Амген Инк. Остеопротегеринсвязующие белки и рецепторы
EP0887408A1 (en) * 1997-05-23 1998-12-30 Smithkline Beecham Plc Wnt-3 oncogene: polypeptides and polynucleotides
US6479255B1 (en) * 1997-05-29 2002-11-12 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Polynucleotides encoding human FRP and fragments thereof
WO1999009152A1 (en) 1997-08-12 1999-02-25 Human Genome Sciences, Inc. Human frezzled-like protein
WO1999026960A2 (en) 1997-11-25 1999-06-03 Millennium Pharmaceuticals, Inc. Genes encoding frizzled-like proteins
WO1999029865A2 (en) 1997-12-12 1999-06-17 The Rockefeller University A protein belonging to the tnf superfamily, nucleic acids encoding same, and methods of use thereof
JPH11196864A (ja) * 1998-01-08 1999-07-27 Deinabekku Kenkyusho:Kk 破骨細胞の分化を誘導する方法
US6110718A (en) * 1998-03-20 2000-08-29 Wayne State University Mammalian putative phosphatidylinositol-4-phosphate-5-kinase
IL148421A0 (en) 1999-09-13 2002-09-12 American Home Prod Pharmaceutical compositions and methods of using secreted frizzled related protein
AU2001243142A1 (en) 2000-02-03 2001-08-14 Hyseq, Inc. Novel nucleic acids and polypeptides
US6600018B1 (en) * 2000-04-10 2003-07-29 The United States Of America As Represented By The Department Of Health And Human Services Secreted frizzled related protein, sFRP, fragments and methods of use thereof
JP2002181893A (ja) * 2000-12-11 2002-06-26 Mitsubishi Electric Corp 半導体装置の検査方法および検査装置

Also Published As

Publication number Publication date
JP2009005704A (ja) 2009-01-15
EP1387854A2 (en) 2004-02-11
JP4029041B2 (ja) 2008-01-09
JP2007300920A (ja) 2007-11-22
US20040077828A1 (en) 2004-04-22
JP4248600B2 (ja) 2009-04-02
PT1387854E (pt) 2012-06-26
ATE550345T1 (de) 2012-04-15
CA2434672C (en) 2014-03-25
CA2434672A1 (en) 2002-07-18
WO2002055547A3 (en) 2003-11-20
EP1387854B1 (en) 2012-03-21
JP4248583B2 (ja) 2009-04-02
DK1387854T3 (da) 2012-07-09
WO2002055547A9 (en) 2002-10-31
US7488710B2 (en) 2009-02-10
US20080145884A1 (en) 2008-06-19
US8334260B2 (en) 2012-12-18
WO2002055547A2 (en) 2002-07-18
AU2002241859B2 (en) 2007-07-19
CY1112875T1 (el) 2016-04-13
JP2005501508A (ja) 2005-01-20

Similar Documents

Publication Publication Date Title
JP4248600B2 (ja) ｓＦＲＰおよびｓＦＲＰと相互作用するペプチドモチーフならびにそれらの使用法
KR101558642B1 (ko) Ｔｇｆ-베타 슈퍼패밀리의 설계자 리간드
CA2412612C (en) Eg-vegf nucleic acids and polypeptides and methods of use
US20040137569A1 (en) Notch receptor ligands and uses thereof
JP2014058551A (ja) 血管新生及び脈管形成のモジュレーターとしてのｒスポンジン
KR101833971B1 (ko) 중간엽 줄기세포 또는 xcl1을 포함하는 근육질환의 예방 또는 치료용 약학적 조성물
US7541431B2 (en) Cristin/R-spondin ligands active in the Wnt signaling pathway and methods, compositions and kits relating thereto
ES2269509T3 (es) Gen expresado altamente en el tejido cartilaginoso.
ES2397327T3 (es) Compuestos asociados a un dominio único de TDF y análogos de los mismos
AU2002241859A1 (en) sFRP and peptide motifs that interact with sFRP and methods of their use
US20030148466A1 (en) Secreted protein, ZTNF9
KR102404717B1 (ko) Tgf-베타 슈퍼패밀리의 ab6 패밀리 디자이너 리간드
WO1998017688A1 (en) Osteometrin related peptides and nucleic acids and diagnosis and therapies using them
KR20080085923A (ko) 백혈구 기능 저해를 위한 조성물 및 방법
WO1998037195A9 (en) Morphogenic proteins
KR20190005240A (ko) Tgf-베타 슈퍼패밀리의 ab6 패밀리 디자이너 리간드를 포함하는 골 및 연골 질환 치료용 조성물 및 그의 이용
US20030032778A1 (en) New member of the human syntaxin/epimorphin family
KR20190005239A (ko) Tgf-베타 슈퍼패밀리의 ab6 패밀리 디자이너 리간드를 포함하는 간질환 치료용 조성물 및 그의 이용
EP3797116A1 (en) Small peptides for inhibiting gabp
WO2005094365A2 (en) Ten-m3 polypeptides and polynucleotides and their methods of use
HK1132298B (en) Eg-vegf nucleic acids and polypeptides and methods of use
AU2002337884A1 (en) Secreted protein, ZTNF9